RSI Overbought Stocks
STAA is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
STAAR SURGICAL CO (STAA) Stock Price & Overview
NASDAQ:STAA • US8523123052
Current stock price
26.68 USD
+1.01 (+3.93%)
At close:
26.68 USD
0 (0%)
After Hours:
The current stock price of STAA is 26.68 USD. Today STAA is up by 3.93%. In the past month the price increased by 49.13%. In the past year, price increased by 40.2%.
STAA Key Statistics
52-Week Range15.585 - 30.81
Current STAA stock price positioned within its 52-week range.
1-Month Range17.5 - 26.9185
Current STAA stock price positioned within its 1-month range.
- Market Cap
- 1.321B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.06
- Dividend Yield
- N/A
STAA Stock Performance
Today
+3.93%
1 Week
+4.50%
1 Month
+49.13%
3 Months
+40.79%
Longer-term
6 Months +3.13%
1 Year +40.20%
2 Years -41.95%
3 Years -62.14%
5 Years -80.53%
10 Years +246.04%
STAA Stock Chart
STAA Stock Screens
STAA currently appears in the following ChartMill screener lists.
STAA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to STAA. When comparing the yearly performance of all stocks, STAA is one of the better performing stocks in the market, outperforming 87.71% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
STAA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to STAA. No worries on liquidiy or solvency for STAA as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
STAA Earnings
On March 3, 2026 STAA reported an EPS of -0.37 and a revenue of 57.80M. The company missed EPS expectations (-734.84% surprise) and missed revenue expectations (-24.81% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateMar 3, 2026
PeriodQ4 / 2025
EPS Reported-$0.37
Revenue Reported57.801M
EPS Surprise -734.84%
Revenue Surprise -24.81%
STAA Forecast & Estimates
17 analysts have analysed STAA and the average price target is 20.97 USD. This implies a price decrease of -21.41% is expected in the next year compared to the current price of 26.68.
For the next year, analysts expect an EPS growth of 93.81% and a revenue growth 19.25% for STAA
Analysts
Analysts69.41
Price Target20.97 (-21.4%)
EPS Next Y93.81%
Revenue Next Year19.25%
STAA Groups
Sector & Classification
STAA Financial Highlights
Over the last trailing twelve months STAA reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS decreased by -421.21% compared to the year before.
Income Statements
Revenue(TTM)239.44M
Net Income(TTM)-80.45M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.81% | ||
| ROE | -23.37% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%26%
Sales Q2Q%18.08%
EPS 1Y (TTM)-421.21%
Revenue 1Y (TTM)-23.72%
STAA Ownership
Ownership
Inst Owners110.46%
Shares49.51M
Float49.19M
Ins Owners0.41%
Short Float %15.72%
Short Ratio5.35
STAA Competitors/Peers
The largest stocks on the US markets in the "Health Care Supplies" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| MDLN | MEDLINE INC-CL A | 30.16 | 58.801B | ||
| ALGN | ALIGN TECHNOLOGY INC | 16.03 | 13.58B | ||
| COO | COOPER COS INC/THE | 12.68 | 12.569B | ||
| SOLV | SOLVENTUM CORP | 10.6 | 11.882B | ||
| LNTH | LANTHEUS HOLDINGS INC | 15.88 | 5.479B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 16.31 | 4.091B | ||
| ICUI | ICU MEDICAL INC | 14.85 | 3.119B | ||
| HAE | HAEMONETICS CORP/MASS | 11.42 | 2.785B | ||
| XRAY | DENTSPLY SIRONA INC | 8.19 | 2.379B | ||
| NEOG | NEOGEN CORP | 27.86 | 2.077B | ||
| UFPT | UFP TECHNOLOGIES INC | 19.58 | 1.542B | ||
| AVNS | AVANOS MEDICAL INC | 24.11 | 1.147B |
Related stock screener links
View all stocks in the Health Care Supplies Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About STAA
Company Profile
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 957 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Company Info
IPO: 1992-02-24
STAAR SURGICAL CO
1911 Walker Ave
Monrovia California CALIFORNIA 92630 US
CEO: Caren Mason
Employees: 957
Phone: 16263037902
STAAR SURGICAL CO / STAA FAQ
What does STAA do?
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 957 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
What is the stock price of STAAR SURGICAL CO today?
The current stock price of STAA is 26.68 USD. The price increased by 3.93% in the last trading session.
Does STAAR SURGICAL CO pay dividends?
STAA does not pay a dividend.
How is the ChartMill rating for STAAR SURGICAL CO?
STAA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the growth outlook for STAAR SURGICAL CO?
The Revenue of STAAR SURGICAL CO (STAA) is expected to grow by 19.25% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for STAA stock?
STAAR SURGICAL CO (STAA) currently has 957 employees.
What is the outstanding short interest for STAAR SURGICAL CO?
The outstanding short interest for STAAR SURGICAL CO (STAA) is 15.72% of its float.